Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low molecular weight heparins.

O M Aguilar1, N S Kleiman

  • 1Baylor College of Medicine, Houston, Texas 77030, USA.

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tomato as a New Host of Erwinia carotovora subsp. carotovora in Argentina.

Plant disease·2019
Same author

Corrigendum to "Meta-Analysis of the Relationship between Deep Brain Stimulation in Patients with Parkinson's Disease and Performance in Evaluation Tests for Executive Brain Functions".

Parkinson's disease·2018
Same author

Meta-Analysis of the Relationship between Deep Brain Stimulation in Patients with Parkinson's Disease and Performance in Evaluation Tests for Executive Brain Functions.

Parkinson's disease·2017
Same author

Transcriptional and functional variation of NF-YC1 in genetically diverse accessions of Phaseolus vulgaris during the symbiotic association with Rhizobium etli.

Plant biology (Stuttgart, Germany)·2012
Same author

Surgical considerations on the use of the percutaneous ventricular assist device TandemHeart in critical aortic valve stenosis.

The Thoracic and cardiovascular surgeon·2009
Same author

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.

Journal of thrombosis and haemostasis : JTH·2007

Low molecular weight heparins (LMWHs) offer predictable anticoagulation for thromboembolic disorders and acute coronary interventions. Further research will determine if LMWHs can replace unfractionated heparin in all standard therapies.

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiology

Background:

  • Heparin, used for nearly 90 years, treats thromboembolic processes but has limitations.
  • Unpredictable anticoagulant effects of unfractionated heparin necessitate improved alternatives.
  • Low molecular weight heparins (LMWHs) were developed to overcome heparin's limitations.

Purpose of the Study:

  • To review the established and emerging applications of low molecular weight heparins (LMWHs).
  • To compare the pharmacologic advantages of LMWHs over unfractionated heparin.
  • To explore the potential for expanded LMWH use in various thromboembolic conditions.

Main Methods:

  • Review of existing literature on heparin and low molecular weight heparins.
  • Analysis of clinical studies involving LMWHs in venous thromboembolic disorders and acute coronary interventions.

Related Experiment Videos

  • Pharmacological comparison of unfractionated heparin and LMWHs.

    • Main Results:

    • LMWHs demonstrate improved predictability and require no laboratory monitoring compared to unfractionated heparin.
    • LMWHs are established treatments for venous thromboembolic disorders.
    • LMWHs have shown efficacy in patients undergoing acute coronary interventions.

    Conclusions:

    • LMWHs offer significant advantages over unfractionated heparin in terms of predictability and monitoring.
    • Current evidence supports LMWH use in specific thromboembolic conditions and acute coronary interventions.
    • Ongoing research is crucial to ascertain the full therapeutic potential of LMWHs as a replacement for unfractionated heparin across all indications.